Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright began coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 target price on the stock.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $4.55 on Thursday. The business’s 50-day moving average is $4.85 and its two-hundred day moving average is $5.22. The firm has a market capitalization of $265.30 million, a PE ratio of -16.25 and a beta of 0.76. Vanda Pharmaceuticals has a 12 month low of $3.46 and a 12 month high of $6.75.

Insider Activity at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in shares of Vanda Pharmaceuticals by 1,184.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares during the last quarter. Monaco Asset Management SAM bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at $1,090,000. Massachusetts Financial Services Co. MA bought a new position in Vanda Pharmaceuticals during the 3rd quarter valued at $864,000. Dimensional Fund Advisors LP grew its holdings in Vanda Pharmaceuticals by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after acquiring an additional 292,172 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth about $143,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.